A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

NCT06640413 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

FAP

Interventions

DRUG: [177Lu]Lu-OncoFAP-23
DRUG: L19IL2

Sponsor

Philogen S.p.A.